A truncated species of apolipoprotein B (B-38.7) in a patient with homozygous hypobetalipoproteinemia associated with diabetes mellitus. 1998

K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

Familial hypobetalipoproteinemia is caused by mutations in the apolipoprotein (apo) B gene. We identified a 57-year-old woman whose plasma total cholesterol and apoB levels were 2.17 mmol/L and 0.03 g/L, respectively. Separation of plasma lipoproteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed the absence of apoB-100 and the presence of a faster-migrating form of apoB with an apparent Mr of 195 kDa. Direct sequencing of a polymerase chain reaction-amplified fragment of the patient's apoB gene DNA revealed a single C-->T transition at nucleotide 5472 that converts glutamine 1755 (CAA) to a stop codon (TAA). We predict this novel nonsense mutation of the apoB gene to produce a truncated protein that contains 1754 amino-terminal amino acid residues of apoB-100. We designated this mutant form of apoB apoB-38.7 by following the centile nomenclature of the apoB species. The same mutation was found in both of her children. The proband revealed clinical findings of retinitis pigmentosa, acanthocytosis, and loss of deep tendon reflexes that are characteristic of severe hypobetalipoproteinemia. In addition, the proband had type II diabetes mellitus with nephropathy, anemia, cholelithiasis, hepatic hemangioma, bronchiectasis, and extensive calcification of major arteries including, the celiac, splenic, and renal. In summary, we have found a novel truncated apoB, apoB-38.7, in a patient with an unusual presentation of hypobetalipoproteinemia that includes diabetes mellitus and extensive arterial calcification.

UI MeSH Term Description Entries
D006995 Hypobetalipoproteinemias Conditions with abnormally low levels of BETA-LIPOPROTEINS (low density lipoproteins or LDL) in the blood. It is defined as LDL values equal to or less than the 5th percentile for the population. They include the autosomal dominant form involving mutation of the APOLIPOPROTEINS B gene, and the autosomal recessive form involving mutation of the microsomal triglyceride transfer protein. All are characterized by low LDL and dietary fat malabsorption. Familial Hypobetalipoproteinemia,Hypo beta Lipoproteinemia,Hypobetalipoproteinemia,Hypo beta Lipoproteinemias
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002114 Calcinosis Pathologic deposition of calcium salts in tissues. Calcification, Pathologic,Calcinosis, Tumoral,Microcalcification,Microcalcinosis,Pathologic Calcification,Calcinoses,Calcinoses, Tumoral,Microcalcifications,Microcalcinoses,Tumoral Calcinoses,Tumoral Calcinosis
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006239 Haplotypes The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX. Haplotype
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes

Related Publications

K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
April 1992, Journal of lipid research,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
September 1996, Arteriosclerosis, thrombosis, and vascular biology,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
January 1989, Arteriosclerosis (Dallas, Tex.),
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
May 1991, The Journal of clinical investigation,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
March 1994, Journal of lipid research,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
May 1994, Human molecular genetics,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
June 1989, The New England journal of medicine,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
June 1987, The Journal of clinical investigation,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
August 1992, Clinical genetics,
K Ohashi, and S Ishibashi, and M Yamamoto, and J Osuga, and Y Yazaki, and S Yukawa, and N Yamada
January 1996, Methods in enzymology,
Copied contents to your clipboard!